Jazz Pharmaceuticals Valuation

Q: What is the Fair Price of JAZZ N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

JAZZ N (MX$2027.24) is trading below our estimate of [[fair value]] (MX$8972.25)

Is JAZZ N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JAZZ N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JAZZ N (MX$2027.24) is trading below our estimate of fair value (MX$8972.25)

Significantly Below Fair Value: JAZZ N is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JAZZ N?

Key metric: As JAZZ N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JAZZ N. This is calculated by dividing JAZZ N's market cap by their current earnings.
What is JAZZ N's PE Ratio?
PE Ratio	16.6x
Earnings	US$414.83m
Market Cap	US$6.89b

JAZZ N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.9x
Enterprise Value/EBITDA	7.6x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does JAZZ N's PE Ratio compare to its peers?

The above table shows the PE ratio for JAZZ N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.1x
LAB B Genomma Lab Internacional. de	15.5x	19.8%	Mex$24.9b
002422 Sichuan Kelun Pharmaceutical	16.3x	11.4%	CN¥48.4b
500488 Abbott India	45.8x	11.0%	₹588.6b
CORT Corcept Therapeutics	42.9x	41.0%	US$6.0b
JAZZ N Jazz Pharmaceuticals	16.6x	17.3%	Mex$6.9b

Price-To-Earnings vs Peers: JAZZ N is expensive based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (13.1x).

Price to Earnings Ratio vs Industry

How does JAZZ N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

24 Companies	Price / Earnings	Estimated Growth	Market Cap

24 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: JAZZ N is good value based on its Price-To-Earnings Ratio (16.6x) compared to the Global Pharmaceuticals industry average (23.6x).

Price to Earnings Ratio vs Fair Ratio

What is JAZZ N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JAZZ N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JAZZ N's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV *

US$3,880.00

-11.8%

12.0%

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

n/a